about
Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilizationHow I treat patients who mobilize hematopoietic stem cells poorlyA novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicityHematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow.Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo.Cellular players of hematopoietic stem cell mobilization in the bone marrow niche.HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization.The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.Targeting the hypoxia-sensing pathway in clinical hematology.The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization.Hierarchy of immature hematopoietic cells related to blood flow and niche.How we mobilize haemopoietic stem cells.Mobilisation strategies for normal and malignant cells.Nichotherapy for stem cells: there goes the neighborhood.Macrophages and regulation of erythropoiesis.Filling the void: allogeneic myeloid cells for transplantation.CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1.Tissue engineered humanized bone supports human hematopoiesis in vivo.G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.Pharmacologic stabilization of HIF-1α increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation.Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells.Epitope recognition of antibodies that define the sialomucin, endolyn (CD164), a negative regulator of haematopoiesis.Engineering a humanized bone organ model in mice to study bone metastases.Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta.Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications.Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle.CD169(+) macrophages are critical for osteoblast maintenance and promote intramembranous and endochondral ossification during bone repair.HIF-1α-stabilizing agent FG-4497 rescues human CD34+ cell mobilization in response to G-CSF in immunodeficient mice.A niche in a dish: pericytes support HSC.Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.[E-selectin, a key regulator of the division of hematopoietic stem cells and their resistance to chemotherapy].Flow cytometry analysis of cell cycling and proliferation in mouse hematopoietic stem and progenitor cells.Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation.Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDRInhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord InjuryComplement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.
P50
Q24299060-43752D19-307E-447D-8129-8C57E38427A5Q28245316-8122FB4A-46AF-4F10-978E-75ECE35BBF5EQ28270598-484FA72F-5633-4B92-9EA8-D129773C7599Q33283654-3CE9FB1C-15D5-4630-AC41-50D0FB43430BQ33555818-8F3867C7-9103-46EA-AF35-29863F2A6D4CQ33717003-6C2503B2-A259-410D-B2EB-2396678DB694Q33717003-8463B379-6A5E-4936-BF77-DA79E90BB672Q34547149-CB46F728-29C0-4F2F-A6C7-690278344D4DQ35838285-E432C353-09B4-4754-9947-98D12FECFCB1Q37167871-ED0C4826-445E-4B2F-B863-54765955FCF3Q37397999-F747306D-EDE6-4215-AB1B-280AAE3F9ACDQ37585456-6755962F-AB4B-406B-BB68-C82E03B3B694Q37791426-311DAB1C-B0D1-42AA-B9EF-C230732DBB36Q37868871-14300ECD-E64A-417A-A3B9-582AEDD60CDFQ37914921-754230DA-9627-40CD-9FAD-A5A8B3D86D71Q37933004-A32CCEF5-D569-44FD-BD29-C748961B174BQ38058023-F3844F6F-CA0A-4176-8647-4BAABFCF6758Q38360512-0D45EC3A-7277-4C0F-B4E8-6E7B7CB3BE5AQ38629613-1FB59AD2-D733-48ED-88BE-020D6A415C0CQ38771403-B049F9D0-8798-4626-AEB7-FA750DFD4EECQ40621006-A2CC84A1-EB31-40E2-A508-99D57657FA60Q40911412-6CC930B2-9C1B-4396-AC36-30FE195E87E7Q41788910-CD09E65A-192D-4221-B0F7-8355FDD3FAE8Q43543334-545780C1-F1EE-4B21-A9F8-C55F8CFF7E27Q44319078-18B59970-D19A-4780-8352-231E7A6B29B2Q45282304-E8D47A80-97FB-4FA9-B22C-5D3F404D5BE6Q46410428-7B4D7358-CA28-43E7-B858-9EB2F8845ADCQ46531963-EF6B92D0-DBDF-40DE-81B6-ADB39A5A59BCQ47991308-34518FD1-7722-4256-A76C-FEB4D9E17635Q48312378-6634BB11-606B-4339-BE72-624C93659490Q50138258-D0AD3669-AB03-4384-84C1-108240C87846Q50633873-82CFA328-A30A-4D21-9E31-28560EC24146Q51072070-89919AF9-CA64-46FE-ADC8-25221362DCD4Q51636063-D7678BA6-17DE-42B6-ACB9-1879DB57FA12Q53113688-1ADEF2AE-1EF0-4EF7-93AD-E559EC34D0AFQ53190879-6B833DC3-150B-403A-BCC4-F7EB1A28CBF7Q54327926-67595737-1FFA-493C-A69D-A5516B642969Q54415335-F7E1F9D8-31F3-4CD0-BF8A-5FDE06FF7A9DQ61797734-ED2B7336-C0A4-4CD7-8D3E-13D33EAA9525Q64120738-CD830EFF-2D0C-4A6B-9168-57B39F4AD998
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jean-Pierre Lévesque
@ast
Jean-Pierre Lévesque
@en
Jean-Pierre Lévesque
@es
Jean-Pierre Lévesque
@nl
Jean-Pierre Lévesque
@sl
type
label
Jean-Pierre Lévesque
@ast
Jean-Pierre Lévesque
@en
Jean-Pierre Lévesque
@es
Jean-Pierre Lévesque
@nl
Jean-Pierre Lévesque
@sl
prefLabel
Jean-Pierre Lévesque
@ast
Jean-Pierre Lévesque
@en
Jean-Pierre Lévesque
@es
Jean-Pierre Lévesque
@nl
Jean-Pierre Lévesque
@sl
P106
P108
P21
P31
P496
0000-0002-7299-6025